Compare AbbVie Inc (ABBV) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Abercrombie & Fitch Co. — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Abercrombie & Fitch Co. trades at $85.64 (market cap $3.96B). The key difference: AbbVie Inc is far larger — about 113.6× Abercrombie & Fitch Co.'s market cap, and AbbVie Inc pays a 2.72% dividend while Abercrombie & Fitch Co. pays none. Which is the better fit depends on your goals.
| ABBV | ANF | |
|---|---|---|
Market Cap | $449.91B | $3.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $129.85 |
52-Week Low | $184.85 | $65.61 |
Enterprise Value | $513.38B | $4.63B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
ANF trades at $89.07, down 3.61% today but maintains strong fundamentals with a P/E of 8.68 and robust profitability metrics including 39.04% ROE. The stock shows technical bullish signals with support at $88 and resistance at $92. Recent earnings beats and 2025 revenue growth to $4.95B demonstrate operational strength, while expansion into third-party footwear and Target partnerships highlight growth initiatives.
ANF presents a compelling value opportunity with attractive valuation multiples and consistent earnings outperformance. Key risks include moderating sales growth and international market softness. Analyst consensus price target of $107.71 suggests 21% upside potential, supported by strong institutional sentiment despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
